Silence Therapeutics Share Discussion Threads

[kreature] 02/1/2020 20:07

Is there anyone there to write any news? Surely it's a farce ? There's no CEO, again.

[1gw] 02/1/2020 19:14

Glad the SoL link was of interest.

Some good news wouldn't go amiss. Some investors doubtless looking around to see how to reshape their portfolios in the New Year, so it would be nice to have some good news to offset the unfortunate loss of the CEO.

I imagine it's tricky to get a new CEO in a couple of weeks over the holiday period, so maybe a bit to wait on that one. And no sign of QPI-1002 having got into the NDA process. SBI scheduled to update on 31st Jan (quarterly results), so if we don't hear beforehand, we should get something then.

They really ought to be able to update us on SLN124 though - if they haven't yet dosed the first patient, what's the hold up? And then there's the unknown of the partnership negotiations. If they really were "becoming advanced" at the end of November, could they announce something before a new CEO is in place?

[kreature] 02/1/2020 14:13

Anyone know where the missing H2/2019 124 trial is?

[mdw1] 02/1/2020 12:08

mms playing games as usual here; the last 1000 @ 335.6 was a buy not a sell.

[kreature] 02/1/2020 11:54

No posts today on lse. Are you expecting a bounce if there’s not much interest? I guess I’m writing this to myself?

[kreature] 02/1/2020 09:51

Somehow I think the trend is backward in going forward. Relentless isn’t it? Are you still adding 1gw, or are you waiting for it to settle? Still no update? It’s like no-one cares isnt it? How is the 124 trial being funded? How many have been recruited? When does the clinical trial begin? Is it still “imminent̶1;?

[vonmoger] 01/1/2020 20:51

Thanks 1gw much appreciated I did not know about the loan data. Also thanks for your post outlining the short average by month very informative. It adds to/confirms my view here.

Atb

[the stigologist] 01/1/2020 12:57

Ali Mortazavi (former Pro Trader, Financier, CEO of Silence Therapuetics), now owns 18% of #ETX which is involved in 'Computational Biology' / AI / Machine Learning



#ETX Mkt Cap £8m (
#PYC Mkt Cap £2m (

It's certainly odd that listed UK small cap players in this Emerging technology field are valued so lowly compared with Private UK 'unicorns' like BenevolentAI ( and ExScientia (

Physiomics RNSed c. £300k of contracts in final weeks of December (Merck and CellCentric). That from a Company which for years had only had revenues of £100-200k annually. Those contracts were in it's 'traditional' Modelling and Simulation business. However their is a new blue sky opportunity in using some of their knowledge in that field in the new field of AI / ML / Personalised Medicine

They said in their recent Annual Report they are 'in discussions with several companies...in the [AI / ML / Personalised Medicine) field'

From their

Annual Report page 11

Personalised Medicine

The personalised medicine and digital health space continues to generate significant interest from both investors and healthcare systems. Many start-ups in this area focus on the use of genetic markers or the pattern-recognition capabilities of artificial intelligence applications however we believe that there is a significant opportunity in the analysis of existing clinical data to identify better ways to treat patient using existing drugs and procedures.

In April 2019 we completed our second Innovate UK funded project in this field in which we developed a demonstration version of a tool to optimise dosing of docetaxel in castrate resistant, metastatic prostate cancer patients. The key outcomes of the project were presented in a poster at the prestigious American Association for Cancer Research Annual Meeting in March 2019. In parallel, working with the Oxford Academic Health Sciences Network, we were able to access some of the UK’s leading clinicians in this space which culminated in our being invited to present at an event jointly sponsored by the Royal Marsden Hospital NHS Trust, the Institute of Cancer Research and the National Institute for Health Research. The Company is now focused on
finding an appropriate commercial partner to gain any required regulatory approvals and make the tool available in a clinical environment.

The Company assesses on an ongoing basis the opportunity for further grant funding either to progress existing projects or start new ones where appropriate but in parallel, the Company is also in discussion with several companies that have an established presence in this field.

[1gw] 01/1/2020 12:13

VM - short positions above 0.5% have to be disclosed to the FCA and are reported in their daily spreadsheet. Short-tracker is a more user-friendly presentation of this data. There are no declared shorts in SLN, according to the FCA spreadsheet.



Euroclear reports monthly average shares on loan (SoL), usually 2 or 3 trading days into the following month. Although SoL can be for purposes other than shorting, it can sometimes give a useful indicator of the overall level of short activity. Click on the "Access as a guest" link and then on the "Monthly stock loan data" icon.



See post 48237 on this bb for the SoL position this year to November, showing the collapse in SoL between September and November.

[vonmoger] 31/12/2019 21:53

1gw

Where does one get the data on short positions for UK stocks? I for one am extremely hopeful that the December data shows a big short position versus history for sln.

Wishing everyone a great 2020 for their trading/investing

Atb and gla

[kreature] 31/12/2019 18:11

Hmmm, well I did say at £6. Oh well

[vonmoger] 31/12/2019 11:56

I'll give you an example in 6 months of a UK us listing that shows impressive growth...

Woodford has depressed plenty of pharmaceutical companies share orices in the uk. I would suggest that there are plenty of pharma holdings that Woodford held that are still and or were undervalued compared to the US comparables. Massive or not I'll leave it up to you to decide. I am sure there are plenty of investors here and elsewhere that have taken advantage of the Woodford overhang/opportunity and the cheap valuations that it created.

[sikhthetech] 31/12/2019 11:35

VonMonger,

Are there massive discrepancies between companies listed in UK and US???
Can you give an example of a pharma which moved from UK listing to US and showed impressive growth after moving...

[vonmoger] 31/12/2019 11:29

And US listing. Like with the old CEO the new one will have a remit and strong incentives to get this listed in the US. The valuation discrepancies between this and the us listed alternatives are very obvious at this share price.

[1gw] 31/12/2019 10:50

Indeed. Have to hope for a bumper update in the New Year. Possibilities are:
- update on trial
- news on quark/teprasiran
- news on deal
- ceo appointment
It will be interesting to see the shares on loan average for December - to see if it is consistent with a "big" short position.

[kreature] 31/12/2019 10:30

Any news on H2 124 ? Seems to be missing ?

[kreature] 31/12/2019 08:32

Maybe not. I guess those large buys yesterday were worked-sells?

[kreature] 31/12/2019 00:57

Thankfully I suppose the market is closed tomorrow ?

[volsung] 30/12/2019 22:36

I will start adding again if we reach 290p or hold over 400p for 3 days or more

[1gw] 30/12/2019 22:34

I seem to remember Dirk Haussecker speculating as to whether they could get $200m (if so I think he suggested it might be worth doing the deal pre-phase 1). I got the impression from one of the recent podcasts that the US listing had taken a back seat to the deal discussions, which were becoming "advanced". The question is what does the loss of the ceo do to the deal timing? Iain Ross has history with sln and experience of doing deals (apparently), so he should be able to take over deal negotiation fairly easily, so long as trust has not been lost.

[vonmoger] 30/12/2019 22:22

1gw

I think it will get 200m or thereabouts upfront. As such I think that the current market cap is way too cheap.

They can change the points at the backend to make the upfront to whatever works I guess.

The only question I have is do they do a deal with lp(a) or any of the other assets before a US listing or after?... It looks today that there will be deals before a listing but only time will tell. Probably by the end of Q1 we will know something.

[1gw] 30/12/2019 22:08

sorry - Big Pharma

[djnzloop] 30/12/2019 22:05

Who is BP? Is that a catch-all?